PHK
KRON

Point72 Hong Kong’s Kronos Bio KRON Stock Holding History

Point72 Hong Kong’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,555
Closed -$9K – 927
2022
Q3 		$9K Sell
2,555
-2,616
-51% -$11.8K ﹤0.01% 1735
2022
Q2 		$19K Buy
+5,171
New +$23.4K ﹤0.01% 1570
2021
Q3 		– Sell
-585
Closed -$14K – 2233
2021
Q2 		$14K Buy
+585
New +$14.8K ﹤0.01% 1688

Other funds holding KRON

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Point72 Hong Kong's KRON Position: Q4 2022 in Review

Point72 Hong Kong sold out of Kronos Bio (KRON) in Q4 2022, closing a stake of 2,555 shares — an estimated $9K sold.

Point72 Hong Kong first reported a position in KRON in Q2 2021 and held it in 3 quarters. The position peaked at $19K in Q2 2022. 97 funds tracked by Wall St. Rank hold KRON as of Q4 2022.

  • Point72 Hong Kong reported no remaining Kronos Bio position as of Q4 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 2,555 Kronos Bio shares in Q4 2022, an estimated $9K.
  • Point72 Hong Kong first reported a position in Kronos Bio in Q2 2021 and held it in 3 quarters.
  • Point72 Hong Kong's Kronos Bio position peaked at $19K in Q2 2022.
  • 97 funds tracked by Wall St. Rank held Kronos Bio as of Q4 2022.

Based on Point72 Hong Kong's 13F filing for Q4 2022, filed 14 Feb 2023.